ICREA researcher and group leader of the Stem Cells and Cancer Laboratory at IRB Barcelona receives an award for his work on cancer.
The prize acknowledges Salvador Aznar Benitah's contributions to transferring knowledge from basic to clinical research.
Researchers headed by IRB Barcelona combine genetic engineering, super-resolution microscopy and biocomputation to allow them to see in 3D the protein machinery inside living cells
Published in the journal Cell, the study unveils key functional features of an assembly of proteins that is vital for animals and plants.
With this new strategy in hand, it will be possible to study cellular protein machinery in health and in disease.
It is a disease of the liver caused by excessive fat deposits in liver cells.
It is now the most prevalent chronic liver disease in industrialised countries and is a major public health concern because it leads to serious liver conditions.
IRB Barcelona organises a new year-long workshop in the life sciences within the series “Crazy About Science”, run by the Fundació Catalunya – La Pedrera.
“Crazy About Biomedicine” seeks to satisfy students’ interest in science and give them the chance to get a taste of what doing science in a top-class centre is like.
The international team achieved it by discovering the rules behind a type of protein structures that are essential for the interaction between proteins and small molecules
IRB Barcelona researcher, Enrique Marcos, is the first author of the study published today in Science
Researchers at IRB Barcelona identify a fundamental role of the JAK/STAT signalling pathway in the development and growth regulation of limbs in Drosophila.
Published in Nature Communications, the study paves the way to research into the function of this pathway in vertebrate development and its possible involvement in human congenital diseases.
The VI National 'Doctores Diz Pintado' Cancer Research Prize acknowledges his work and scientific career.
A bioinformatics analysis of pairing 64 drugs used to treat breast cancer allows researchers at IRB Barcelona to identify 10 previously untested combinations with potential to tackle resistance to breast cancer treatment.
In spite of the many drugs available to treat breast cancer, resistance continues to be a problem.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.